Strategic expansion strengthens Finalsite’s mission to help schools deliver meaningful, connected experiences for families across every interaction.

GLASTONBURY, Conn., Sept. 28, 2026 — Finalsite, a leading K–12 platform for school engagement, enrollment and communications, has expanded its payments capabilities through its recent acquisition of RevTrak, a leading digital payments provider serving more than 13,000 schools nationwide.

RevTrak builds on Finalsite’s existing tuition and billing solutions by extending its reach across everyday school payments—from meals and athletics to activities, events and fees. For more than 30 years, RevTrak has helped schools simplify how they collect, manage and track money, supporting the shift from cash, checks and manual processes to digital payments. Its technology combines the convenience families expect with the reporting, reconciliation tools and integrations schools need.

This complementary acquisition strategically expands Finalsite’s K–12 platform. By pairing RevTrak’s trusted payments technology with Finalsite’s school experience solutions, Finalsite offers an integrated, modern solution across the full family journey—enhancing convenience for families and operational efficiencies for schools.

“Families experience their school through every interaction—from their first website visit to enrolling a child, receiving an update or paying for a field trip,” said Jim Calabrese, Finalsite CEO. “Making those moments easier for families must also mean making them easier for school teams to deliver. RevTrak brings proven payments expertise to our broader strategy: a more connected school experience with less administrative complexity behind it.”

Together, Finalsite and RevTrak serve more than 50,000 schools worldwide. Finalsite’s scale and commitment to investment in product innovation, enterprise-grade security, and customer success will accelerate delivery of new payments capabilities to schools while unlocking an easier payment experience for parents.

Finalsite is a portfolio company of Veritas Capital (“Veritas”), a leading investor operating at the intersection of technology and government.

About Finalsite
Finalsite is a K–12 Family Experience Platform serving more than 40,000 schools worldwide, making school easier for families and simpler for school teams to manage.

From the first website visit to enrollment, communications and payments, Finalsite connects the interactions that shape a family’s relationship with their school. By bringing together essential tools, data and workflows, Finalsite helps schools and districts reduce administrative complexity, personalize communications and strengthen enrollment and retention—giving staff more time to serve students and families.

Finalsite is headquartered in Glastonbury, Connecticut with employees across the U.S. and internationally in Canada, Europe and Asia. For more information, please visit www.finalsite.com.

About RevTrak
RevTrak is the complete school payment platform purpose-built for K–12 districts. For more than 30 years, RevTrak has helped district finance teams simplify how schools collect, manage, and track money — across fees, meals, athletics, events, fundraising, registrations and more. Trusted by more than 13,000 schools nationwide, RevTrak integrates with the tools districts already use to give families a modern payment experience and give staff the reporting and reconciliation tools they need.

About Veritas Capital
Veritas is a longstanding technology investor with $54 billion of assets under management and a focus on companies operating at the intersection of technology and government. The Firm invests in companies that provide mission-critical products, services, and software, primarily technology and technology-enabled solutions, to government and commercial customers worldwide. Veritas seeks to create value by strategically transforming the companies in which it invests through organic and inorganic means. Leveraging technology to make a positive impact across vitally important areas, such as healthcare, education, energy, and national security, is core to the Firm. Veritas is a proud steward of national and global assets, focused on improving the quality of healthcare while reducing cost, advancing educational systems, accelerating energy transition, and protecting our nation and allies. For more information, visit www.veritascapital.com.

Finalsite Media Contact
Jon Kannenberg
[email protected] 

Veritas Media Contact
News Media
Prosek Partners
[email protected] 

SOURCE Finalsite

Partnership Will Support New Age Medical’s National Expansion, Entry into New Specialties, and M&A-Driven Growth

STAMFORD, Conn., Sept. 28, 2026 — Avesi Partners (“Avesi”) announced that it has made an investment in New Age Medical (“New Age” or the “Company”), a leading MedTech hub serving the spinal surgery market. Avesi has partnered alongside New Age’s founder and CEO, Kevin Bly, and the Company’s existing management team to support New Age’s mission of enhancing patient care and driving operational efficiency by optimizing and accelerating the flow of medical solutions from manufacturers, through reps, to hospitals, surgeons, and patients.

Headquartered in St. Louis, MO, New Age Medical sits at the intersection of medical device manufacturers, hospitals & ambulatory surgery centers (“ASCs”), surgeons, and medical device sales representatives. New Age works nationwide with 85+ original equipment manufacturers (“OEMs”), 100+ reps, 200+ hospitals/ASCs, and 350+ surgeons, ensuring leading technology is accessible to those who need it. The New Age model reduces supply chain complexity and enables vendor consolidation for hospitals and ASCs, while bringing surgeons and patients the most innovative products OEMs have to offer.

“When we founded New Age Medical in 2012, the goal was simple: make it easier for surgeons to get the right products for their patients, and easier for the manufacturers building those products to reach them,” said Kevin Bly, Founder and Chief Executive Officer of New Age Medical. “Avesi shares our conviction that durable growth is the result of doing right by every stakeholder we serve—surgeons, hospitals, manufacturers, and the reps who bring it all together. The cultural alignment between our two organizations was clear from our very first conversation, as was a shared, growth-oriented mindset. With Avesi’s commitment and resources behind us, we can extend best-in-class product access to more surgeons, more facilities, more reps and ultimately more patients across the country.”

“Avesi has targeted innovative businesses that help hospitals and health systems deliver the highest standards of care while reducing administrative burden,” said Pete Tedesco, Managing Director at Avesi. “New Age delivers this value to its stakeholders and operates in a large, growing market with substantial opportunity to expand. We look forward to pairing our resources and healthcare expertise with the talented team at New Age to continue delivering exceptional service and extend the Company’s impact across new specialties and markets.”

“New Age Medical is one of a kind in its sector given its long-term track record of growth, the strength of its relationships across surgeons, reps, OEMs, and facilities, and the differentiated value it delivers to each,” said Chris Laitala, Managing Partner at Avesi. “Our team at Avesi is excited to work alongside management in the coming years to further expand the Company’s reach and capabilities.”

About New Age Medical

New Age Medical is the MedTech hub that optimizes and accelerates the flow of medical solutions from manufacturers, through reps, to hospitals and surgeons, all with the overarching goal of enhancing patient care and driving operational efficiency. Founded in 2012 and headquartered in St. Louis, MO, New Age works with 85+ OEMs, 100+ reps, 200+ hospitals/ASCs, and 350+ surgeons nationwide, providing top-quality spinal implants, orthobiologics, and related products to ensure exceptional patient care.

For more information, visit https://newagemedical.com/ or https://www.linkedin.com/company/new-age-medical-llc/.

About Avesi Partners

Avesi Partners, with offices in Stamford, CT and Richmond, VA, and over $2.2 billion in assets under management, focuses on partnering with lower-middle market privately held and family-owned businesses in key sectors of the economy, including healthcare services and technology, and business services. Avesi seeks to provide the expertise and resources to empower businesses to attain their full vision in a time and capital efficient manner. Avesi’s goal is to collaborate with families, founders, and executives to accelerate growth and expansion while positioning the businesses to achieve long-term success and enduring value. Target platform companies typically have approximately $5-30 million of EBITDA.

For further information, visit www.avesipartners.com or www.linkedin.com/company/avesi-partners.

New Age Medical Contact
[email protected]

Avesi Contact
[email protected]

SOURCE Avesi Partners

NEW YORK, Sept. 28, 2026 — Infrastructure Capital Advisors, LLC (Infrastructure Capital), a leading provider of investment management solutions designed to meet the needs of income-focused investors, is excited to declare distributions for the Infrastructure Capital Nasdaq Option Income ETF (QVOL), Infrastructure Capital Bond Income ETF (BNDS), Infrastructure Capital Small Cap Income ETF (SCAP), and Infrastructure Capital Equity Income ETF (ICAP). QVOL has declared a distribution increase by $0.05 from $1.04 to $1.09 per share. SCAP has declared a distribution increase by $0.005 from $0.25 to $0.255 per share. ICAP has declared a distribution increase by $0.005 from $0.25 to $0.255 per share. BNDS has declared a distribution increase by $0.0025 from $0.34 to $0.3425 per share.

QVOL intends to target an annualized distribution rate range of between 12% and 15% through option premiums earned from selling call options and dividends received from the Fund’s equity holdings. This target range reflects Infrastructure Capital’s expectations based on the options premiums QVOL seeks to generate and the annualized effect of those premiums. There is no assurance QVOL will achieve its target annualized distribution rate range, and the target annualized distribution rate range does not represent a 12% to 15% yield or a 12% to 15% total return. Actual distributions may be higher or lower depending on market conditions and QVOL’s results. Distributions may include a portion classified as return of capital. Return of capital generally represents a return of a shareholder’s invested capital rather than traditional income such as dividends or interest.

QVOL has declared a monthly distribution of $1.09 per share ($13.08 per share on an annualized basis). 
 

• Ex-Date: Tuesday, September 29, 2026
• Record Date: Tuesday, September 29, 2026
• Payable Date: Wednesday, September 30, 2026

SCAP has declared a monthly distribution of $0.255 per share ($3.06 per share on an annualized basis). 

• Ex-Date: Tuesday, September 29, 2026
• Record Date: Tuesday, September 29, 2026
• Payable Date: Wednesday, September 30, 2026

ICAP has declared a monthly distribution of $0.255 per share ($3.06 per share on an annualized basis). 

• Ex-Date: Tuesday, September 29, 2026
• Record Date: Tuesday, September 29, 2026
• Payable Date: Wednesday, September 30, 2026

BNDS has declared a monthly distribution of $0.3425 per share ($4.11 per share on an annualized basis). 

• Ex-Date: Tuesday, September 29, 2026
• Record Date: Tuesday, September 29, 2026
• Payable Date: Wednesday, September 30, 2026

Infrastructure Capital Advisors expects to declare future distributions on a monthly basis. Distributions are planned, but not guaranteed, for every month. For more information about each Fund’s distribution policy, its 2026 distribution calendar, or tax information, please visit each Fund’s web site for more information.

QVOL is designed to deliver an attractive income stream through a disciplined options-writing strategy, while maintaining the potential for capital appreciation through selective equity positioning. The fund invests at least 80% of its net assets in equity securities and option contracts tied to the Nasdaq, utilizing both quantitative and qualitative analysis to identify relative value opportunities.

“In the current market environment, investors are seeking consistent income without giving up exposure to growth, particularly in the information technology sector,” said Jay Hatfield, CEO and CIO of Infrastructure Capital Advisors. “QVOL is built to monetize the increased volatility we’ve seen across Nasdaq-listed companies through active options strategies while maintaining the careful and pragmatic approach to portfolio and product construction that Infrastructure Capital has become well known for.”

Infrastructure Capital’s suite of dynamic ETFs leverages the firm’s established investment process, including company-level fundamental modeling, valuation-driven price targets, and active volatility management. The firm manages over $4 billion in assets as of 09/28/2026 and delivers income-focused investment solutions to their clients.

QVOL joined the Infrastructure Capital ETF lineup, which includes the Virtus InfraCap U.S. Preferred Stock ETF (NYSE Arca: PFFA), InfraCap REIT Preferred ETF (NYSE Arca: PFFR), InfraCap MLP ETF (NYSE Arca: AMZA), the Infrastructure Capital Equity Income ETF (NYSE Arca: ICAP), Infrastructure Capital Small Cap Income ETF (NYSE Arca: SCAP), Infrastructure Capital Bond Income ETF (NYSE Arca: BNDS) the Infrastructure Capital Preferred Income UCITS ETF (FTSE MIB: PFFI), the Infrastructure Capital S&P 500 Option  Income UCITS ETF (FTSE MIB: SPYC), and  Infrastructure Capital Nuclear Renaissance UCITS ETF (FTSE MIB: NUKZ).

Hatfield is the lead Portfolio Manager for all of the Infrastructure Capital funds and brings more than 30 years of experience to his work on behalf of clients. As of the date of this release, the firm manages more than $4 billion in total assets.

Follow Infrastructure Capital on social media for all of the firm’s need-to-know market commentary and economic outlook at:

Monthly Market and Economic Webinar – Jay Hatfield

Register for our monthly Market & Economic Insights webinar series. Can’t join live each month?  Register anyway and we will email you a playback video link

Income Investing with Infrastructure Capital

Jay D. Hatfield is the Chief Investment Officer for all of the Infrastructure Capital funds and brings more than 30 years of experience to his work on behalf of clients. As of the date of this release, Infrastructure Capital manages over $4B in total assets. 

BNDS ETF strategy is to target high yield investments across fixed-income securities, predominately focusing on corporate bonds. Infrastructure Capital seeks positive security selection versus the benchmark by using a mix of quantitative and qualitative analysis with an emphasis on fixed-income securities that are believed to be undervalued when considering factors such as term premium, credit premium, liquidity premium, industry, sector, and market capitalization.

SCAP ETF seeks total return through a blended approach of capital appreciation and current income. The Fund focuses primarily on the securities of U.S.-listed small cap companies, which is defined as companies with a market capitalization within the range of companies in the Russell 2000 Index. Investments may take the form of common stocks, preferred stocks, convertible securities, debt instruments, equity-linked notes, or other small cap-focused ETFs.

ICAP ETF will primarily invest in equity securities of companies with a strong track record of paying dividends during normal market conditions. The Fund’s portfolio of equities will generally be a diversified selection of securities, including a broad cross-section of sectors and sub-sectors, such as REITs, Utilities, Industrials, pipelines, and financials.

About Infrastructure Capital Advisors
Infrastructure Capital Advisors, LLC (ICA) is an SEC-registered investment advisor that manages exchange traded funds (ETFs) and a series of hedge funds. The firm was formed in 2012 and is based in New York City. ICA seeks total-return opportunities driven by catalysts, largely in key infrastructure sectors. These sectors include energy, real estate, transportation, industrials and utilities. It often identifies opportunities in entities that are not taxed at the entity level, such as master limited partnerships (“MLPs”) and real estate investment trusts (“REITs”). It also looks for opportunities in credit and related securities, such as preferred stocks.

Current income is a primary objective in most, but not all, of ICA’s investing activities.

Consequently, the focus is generally on companies that generate and distribute substantial streams of free cash flow. This approach is based on the belief that tangible assets that produce free cash flow have intrinsic values that are unlikely to deteriorate over time. For more information, please visit infracapfunds.com.

The information contained herein represents our subjective belief and opinions and should not be construed as investment, tax, legal, or financial advice. Investors should consider the investment objectives, risks, charges, and expenses carefully before investing. Please read the prospectus carefully before investing. For more information about Fund strategies or Infrastructure Capital, please reach out to Craig Starr at 212-763-8336 ([email protected]).

The Nasdaq Composite is a stock market index composed of thousands of stocks listed on the Nasdaq Stock Market®, with a particular emphasis on technology-related companies. Established in 1971, it is known for featuring a wide range of companies—from established giants like Apple and Microsoft to smaller, fast-growing firms—reflecting a broad cross-section of the U.S. technology sector. The index is market capitalization-weighted, meaning that larger companies have a greater influence on its overall performance, and it is commonly used as a benchmark to gauge the health and trends of the technology-driven segments of the American economy.

Investors should consider the investment objectives, risks, charges, and expenses carefully before investing. Please read the prospectus carefully before investing. For more information about the Fund, Fund strategies or Infrastructure Capital, please reach out to Craig Starr at 212-763-8336 ([email protected]).

A word about QVOL Risk:  Investing involves risk. Principal loss is possible. The Fund is a recently organized investment company with no operating history prior to the date of this Prospectus. As a result, prospective investors have no track record or history on which to base their investment decision. Derivatives may pose risks in addition to and greater than those associated with investing directly in securities, currencies or other investments, including risks relating to leverage, imperfect correlations with underlying investments or the Fund’s other portfolio holdings, high price volatility, lack of availability, counterparty credit, liquidity, valuation and legal restrictions. Options transactions involve special risks that may make it difficult or impossible to close a position when the Fund desires. The prices of securities the Adviser believes are undervalued may not appreciate as anticipated or may go down, the valuations may never improve or returns on value equity securities may be less than returns on other styles of investing or the overall stock market. Leverage is investment exposure which exceeds the initial amount invested. When the Fund borrows money for investment purposes, or when the Fund engages in certain derivative transactions, such as options, the Fund may become leveraged. A high portfolio turnover rate (portfolio turnover in excess of 100% of the average value of the Fund’s portfolio) has the potential to result in the realization and distribution to shareholders of higher capital gains, which may subject you to a higher tax liability. Please see prospectus for discussion of risks. QVOL fund distributor, Quasar Distributors, LLC.

A word about SCAP risk: Investing involves risk, including possible loss of principal. An investment in the Fund may be subject to risks which include, among others, investing in equities securities, dividend paying securities, utilities, small-, mid- and large-capitalization companies, real estate investment trusts, master limited partnerships, foreign investments and emerging, debt securities, depositary receipts, market events, operational, high portfolio turnover, trading issues, active management, fund shares trading, premium/discount risk and liquidity of fund shares, which may make these investments volatile in price. Foreign investments are subject to risks, which include changes in economic and political conditions, foreign currency fluctuations, changes in foreign regulations, and changes in currency exchange rates which may negatively impact the Fund’s returns. Small and Medium-capitalization companies, foreign investments and high yielding equity and debt securities may be subject to elevated risks. The Fund is a recently organized investment company with no operating history. Please see prospectus for discussion of risks. Diversification cannot assure a profit or protect against loss in a down market. SCAP is distributed by Quasar Distributors, LLC.

A word about ICAP Risk: Investing involves risk, including possible loss of principal. An investment in the Fund may be subject to risks which include, among others, investing in equities securities, dividend paying securities, utilities, preferred stocks, leverage, short sales, small-, mid- and large-capitalization companies, real estate investment trusts, master limited partnerships, foreign investments and emerging, debt securities, depositary receipts, market events, operational, high portfolio turnover, trading issues, options, active management, fund shares trading, premium/discount risk and liquidity of fund shares, which may make these investments volatile in price. Foreign investments are subject to risks, which include changes in economic and political conditions, foreign currency fluctuations, changes in foreign regulations, and changes in currency exchange rates which may negatively impact the Fund’s returns. Small and Medium-capitalization companies, foreign investments, options, leverage, short sales, and high yielding equity and debt securities may be subject to elevated risks. The Fund is a recently organized investment company with no operating history. Please see prospectus for discussion of risks. ICAP fund distributor, Quasar Distributors, LLC.

A word about BNDS risk:  Investing involves risk, including possible loss of principal. An investment in the Fund may be subject to risks which include, among others, investing in fixed income securities, dividend paying securities, utilities, small-, mid- and large-capitalization companies, real estate investment trusts, master limited partnerships, debt securities, market events, operational, high portfolio turnover, trading issues, active management, fund shares trading, premium/discount risk and liquidity of fund shares, which may make these investments volatile in price.  Small and Medium-capitalization companies, and high yielding equity and debt securities may be subject to elevated risks.  New Fund Risk. The Fund is a recently organized investment company with no operating history prior to the date of this Prospectus. As a result, prospective investors have no track record or history on which to base their investment decision. Debt Securities Risk. Increases in interest rates typically lower the value of debt securities held by the Fund. Investments in debt securities include credit risk. Credit Risk. An issuer of debt securities may not make timely payments of principal and interest and may default entirely in its obligations. A decrease in the issuer’s credit rating may lower the value of debt securities. Interest Rate Risk. Securities could lose value because of interest rate changes. For example, bonds tend to decrease in value if interest rates rise. Derivatives Risk. Derivatives may pose risks in addition to and greater than those associated with investing directly in securities, currencies or other investments, including risks relating to leverage, imperfect correlations with underlying investments or the Fund’s other portfolio holdings, high price volatility, lack of availability, counterparty credit, liquidity, valuation and legal restrictions. Options Risk. Options transactions involve special risks that may make it difficult or impossible to close a position when the Fund desires. A fund that purchases options, which are a type of derivative, is subject to the risk that gains, if any, realized on the position, will be less than the amount paid as premiums to the writer of the option. BNDS fund distributor, Quasar Distributors, LLC.

The Funds are distributed either by Quasar Distributors, LLC or by VP Distributors, LLC, an affiliate of Virtus ETF Advisers, LLC. QVOL, ICAP, SCAP, and BNDS ETFs are distributed by Quasar Distributors LLC. PFFA, PFFR, and AMZA ETFs are distributed by VP Distributors, LLC an affiliated of Virtus ETF Advisers, LLC.

Nasdaq® is a registered trademark of Nasdaq, Inc. (which with its affiliates is referred to as the “Corporation”) and is licensed for use by Infrastructure Capital Advisors, LLC. The Product has not been passed on by the Corporations as to its legality or suitability. The Product is not issued, endorsed, sold, or promoted by the Corporations. THE CORPORATIONS MAKE NO WARRANTIES AND BEAR NO LIABILITY WITH RESPECT TO THE PRODUCT.

SOURCE Infrastructure Capital Advisors

SHANGHAI, Sept. 28, 2026 — MOYOM Biotech, a biotechnology company specializing in regenerative aesthetic biomaterials, today announced that it has completed a new financing round from the Cathay Consumer Co-Creation Fund, managed by Cathay Capital. The investment marks an important milestone in the company’s development and will support its next phase of global growth.

The fund was jointly established by Cathay Capital, L’Oréal and the Shanghai Jing’an District Government to foster innovation in beauty, health and skin science. Cathay Capital has built a global investment ecosystem spanning consumer, healthcare and technology, with notable investments including Moonshot AI (Kimi), autonomous driving company Momenta, U.S. fintech company Chime, digital asset platform Ledger, global delivery platform Glovo and AI biotechnology company Owkin.

In addition to identifying emerging brands, investment platforms of this kind can give strategic partners earlier access to emerging technologies, supply-chain capabilities and innovation in adjacent industries. Cathay Capital’s investment in MOYOM reflects growing interest in technologies and biomaterial innovations with the potential to shape the next generation of the beauty and medical aesthetics industry.

Founded in 2018, MOYOM focuses on nanomedical biomaterials and Class III absorbable implantable medical devices, particularly calcium hydroxylapatite (CaHA) regenerative materials. Its flagship brand, Aphranel^®, brings MOYOM’s proprietary biomaterials research to market. Positioned as a new-generation CaHA biostructurer, Aphranel^® is designed to combine immediate structural support, regenerative stimulation and complete biodegradation.

MOYOM’s technology platform is built around two proprietary technologies: ACD-MT^® raspberry-shaped through-hole CaHA microspheres and PCD-ETT^® physically cross-linked CMC gel technology. Together, they are engineered to deliver structural performance, support regenerative interaction and enable controlled biodegradation.

Aphranel^® received Class III medical device registration from China’s National Medical Products Administration (NMPA) in February 2025 and certification under the European Union Medical Device Regulation (EU MDR) in May 2026, establishing a regulatory foundation for international expansion. Since its commercial launch in May 2025, Aphranel^® has been introduced in more than 700 medical aesthetics clinics across China, demonstrating increasing market adoption alongside continued scientific and regulatory progress.

With its proprietary technology platform, key regulatory milestones and growing market presence, MOYOM is entering a new phase of growth. Leveraging Cathay Capital’s global ecosystem, the company plans to accelerate clinical translation, pursue additional regulatory approvals and expand into overseas markets, while continuing to invest in next-generation regenerative biomaterials.

The financing will support MOYOM’s efforts to bring biomaterial innovation originating in China to international markets and establish Aphranel^® as a science-driven regenerative aesthetics brand with global reach.

About MOYOM Biotech

Founded in 2018, MOYOM Biotech develops regenerative aesthetic biomaterials and absorbable implantable medical devices. The company developed Aphranel^®, its flagship CaHA-based regenerative aesthetics brand.

SOURCE MOYOM Biotech

SAN JOSE, Calif., Sept. 25, 2026 — Overlord Labs, Inc., a fabless semiconductor company building battery intelligence infrastructure for compute-intensive, battery-powered devices, today announced the close of its oversubscribed Seed financing, bringing total funding raised to-date to $10 million. The total comprises $7.25 million in Seed financing and the remainder in non-dilutive strategic development funding.

The financing comes as Overlord Labs transitions from tape-out to product validation, following the successful bring-up of its flagship GENESIS™ Battery Intelligence IC, built on the company’s proprietary Silicon × Algorithm Architecture. With silicon operating, the company is advancing validation and preparing to begin customer sampling.

The $4.35 million Seed extension was led by Band of Angels and drew participation from Foothill Ventures, Unlock Pacific Ventures, NuFund Venture Group, Sand Hill Angels and Castle Fund. The round also included returning strategic angel investors, who backed Overlord Labs in its earlier financings and invested additional capital in the extension alongside the new institutional investors.

As compute continues moving to the edge, battery-powered devices are placing unprecedented demands on power efficiency, thermal management, safety and runtime. Traditional fixed-function battery management ICs were not designed for this new generation of intelligent products. Overlord Labs’ Silicon × Algorithm Architecture solves this by building battery intelligence directly into silicon, giving OEMs a more adaptable foundation for these systems.

The first GENESIS™ device targets single-cell systems and is designed to support both established and emerging battery chemistries, including silicon-anode cells. Initial applications include smart glasses, wearables, hearables and other edge AI devices, where rising compute demands must be met within tight battery and form-factor limits.

Overlord Labs will use the capital to complete validation and qualification, support customer sampling and Tier-1 OEM engagements, expand its firmware and battery-algorithm capabilities, and build the production infrastructure needed for commercial scale. The company is targeting volume production in the first half of 2027.

“We started Overlord Labs because battery management architectures were no longer keeping pace with the devices they power,” said Richard Nicholson, Co-Founder and Chief Executive Officer of Overlord Labs. “We now have working silicon, active customer engagement and an investor syndicate, including angels who came back to invest again, that understands the scale of the opportunity. This capital gives us the resources to move GENESIS™ through customer validation and toward production.”

“Hardware OEMs have historically faced a rigid trifecta of trade-offs: performance, form factor, and battery life,” said Carlos Rodriguez, Co-Founder and Chief Operating Officer of Overlord Labs. “We engineered GENESIS™ to break those constraints, giving product teams the software-defined silicon they need to scale all three without compromise. With the Seed financing complete, our focus is getting GENESIS™ into customers’ hands and building the foundation to scale.”

About Overlord Labs
Overlord Labs is a fabless semiconductor company building battery intelligence infrastructure for the next generation of compute-intensive, battery-powered devices. Powered by its proprietary Silicon × Algorithm Architecture, the company’s GENESIS™ Battery Intelligence Platform integrates advanced battery intelligence directly into silicon, enabling OEMs to improve runtime, safety, performance, and design flexibility. Initially focused on wearables, smart glasses, and edge AI devices, the platform is designed to scale across a broad range of battery-powered systems. Headquartered in San Jose, California, Overlord Labs is engineering battery intelligence from the silicon up.

Media Contact
Dianna Rodriguez
Marketing Manager
[email protected]

SOURCE Overlord Labs

Designed for autistic individuals, neurodivergent children, and sensory seekers, the innovative play structure combines gentle, full-body mild-to-moderate or deep pressure input with physical exertion to promote self-regulation and calm.

NORTH LAS VEGAS, Nev., Sept. 25, 2026 — Wriggle Box LLC today announced the official launch of its Indiegogo crowdfunding campaign for Wriggleworm, a novel sensory regulation play structure engineered to provide soothing, full-body mild-to-moderate or deep pressure input paired with beneficial physical movement.

Inspired by a simple yet powerful premise—What is the greatest full-body sensory experience a person can have? —the Wriggleworm was developed to mimic the sensation of digging through the earth as a worm does, offering calming, uniform pressure from all sides as the user moves through it.

Unlike traditional sensory squeeze tools or compression tubes, Wriggleworm combines tactile and proprioceptive feedback with active physical exertion. This dual-action approach aids sensory regulation, decreases anxiety, and promotes focus for autistic individuals, children with ADHD, sensory processing differences, and anyone who benefits from sensory-based movement.

Key Features & Benefits:

• Full-Body Sensory Input: Delivers mild-to-moderate or deep, even pressure across the entire body as users maneuver through the structure.
• Integrated Physical Exertion: Encourages gross motor play and physical movement, turning sensory therapy into an engaging play experience.
• Designed for Regulation: Helps users self-regulate when overwhelmed, providing a safe and controlled output for excess energy.
• Inclusive & Purpose-Built: Created with input and inspiration directly from the neurodivergent community to address unmet sensory needs in homes, schools, and therapy centers.

“Sensory regulation is essential for wellbeing, yet many existing tools only engage one part of the body or lack the dynamic movement required to achieve true calm,” said Adrian Krosnick, Founder of Wriggle Box LLC. “The Wriggleworm bridges that gap by turning deep-pressure sensory therapy into a fun, full-body experience that empowers users to self-regulate on their own terms.”

The Indiegogo campaign offers early backers exclusive rewards and early-bird pricing to help bring the first production run of Wriggleworm to homes, occupational therapy clinics, and classrooms nationwide.

To learn more about Wriggleworm or support the campaign, visit the Indiegogo campaign page here: https://www.indiegogo.com/en/projects/wigglebox/wriggleworm

About Wriggle Box LLC

Wriggle Box LLC is a mission-driven company dedicated to designing functional, joyful, and inclusive sensory solutions for autistic and neurodivergent individuals, sensory seekers, and occupational therapy professionals.

Media Contact

Name: Adrian Krosnick Title: Founder Company: Wriggle Box LLC Email: [email protected]Phone: 1-702-659-9419 Website/Campaign: https://www.indiegogo.com/en/projects/wigglebox/wriggleworm Media Kit / Images: https://youtu.be/xDviFJ4k3b4?si=eSAinRzcXR3ToZL6

SOURCE Wriggle Box LLC

SAN MATEO, Calif., Sept. 25, 2026 — Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting and multi-specific therapies, today announced its selection as a winner of the 2026 Endpoints 11, the annual list of the 11 most promising private biotechnology companies curated by the Endpoints News editorial team.

Founded in July 2024, Kali was selected by Endpoints News editors on the strength of its differentiated T-cell engager platform and the pace of its execution — in just over two years, the company has advanced two candidates into the clinic and licensed its lead program to Sanofi. The 2026 honorees were chosen following a monthslong selection process spanning hundreds of private companies and were announced at an awards gala held at The State Room in Boston on Thursday, September 24, 2026.

“We are honored to be named an Endpoints 11 company and to stand alongside a group of teams taking real scientific risk,” said Weihao Xu, Founder and Chief Executive Officer of Kali Therapeutics. “This recognition belongs to everyone at Kali who has moved our proprietary CD3-masking platform from an engineering idea to two molecules in the clinic in a little over two years — and, most of all, to the patients and investigators who have joined our trials. Our ambition has not changed: to pursue a durable immune reset that has the potential to offer people with autoimmune disease something more than another chronic therapy.”

The award follows a year of rapid progress, including FDA clearance of the Investigational New Drug application for KT501, first patient dosing in the Phase 1a rheumatoid arthritis trial in March 2026, and a worldwide exclusive license of KT501 to Sanofi for $180 million in upfront and near-term payments, with up to $1.05 billion in potential milestones and tiered royalties.

“We backed Weihao and this team at founding and worked closely with them since then. The pace of execution has been remarkable — from company formation to the clinic and a worldwide partnership with Sanofi in roughly two years,” said Derek Yuan, Ph.D., Partner at LYFE Capital, Kali’s earliest institutional investor, and a member of the company’s Board of Directors. “What drew us in from the start was the promise of durable remission for patients. Kali’s proprietary engineering offers a way to bring the potency of T-cell engagers to autoimmune disease without accepting the toxicity that has limited the modality, and the data generated so far have reinforced that thesis. We are proud to support Kali from the beginning and to continue backing the team as the platform expands.”

Kali’s proprietary CD3-masking platform is designed to decouple potency from toxicity, enabling deep B-cell depletion in both peripheral blood and tissue while limiting cytokine release. The approach underpins a pipeline that includes KT502, a CD19 x CD3 bispecific T-cell engager in Phase 1 clinical trial, and KT209, a CD19 x CD20 x CD3 trispecific antibody with IND-enabling activities underway and a first-in-human study planned for the first half of 2027. Kali is also extending the platform beyond B-cell depletion, applying the same masking approach to additional cell types implicated in autoimmune and inflammatory disease.

About Kali Therapeutics

Founded in July 2024, Kali Therapeutics is a clinical-stage biotechnology company headquartered in San Mateo, California, dedicated to developing transformative therapies for autoimmune and inflammatory diseases. By combining advanced protein engineering and high-throughput experimental techniques, Kali Therapeutics streamlines the drug discovery and research process. The company’s proprietary immune cell engager platform enables precise optimization of the functionality, manufacturability, and developability of biologics with first-in-class or best-in-class potential, leveraging T-cell engagers with precise targeting and controlled cytotoxicity to enable a transformative immune system reset and regeneration. For more information, visit kalitherapeutics.com and follow the company on LinkedIn.

About the Endpoints 11

The Endpoints 11 is an annual award from Endpoints News recognizing the most promising private biotechnology companies in the industry. Honorees are chosen by the Endpoints editorial team following a monthslong review, with an emphasis on differentiated science, strong leadership, and the financial capacity to execute. Endpoints News is part of the Financial Times’ FT Specialist group. Full profiles of the 2026 honorees are available at endpoints.news.

SOURCE Kali Therapeutics

Roundtable held during UN General Assembly week examined how investment, technology, and new models of care can close the global women’s health gap

NEW YORK, Sept. 25, 2026 — Global leaders from healthcare, investment, philanthropy, and government called for greater investment in scalable, integrated models of women’s healthcare at “The $1 Trillion Case for Women’s Health,” a high-level roundtable convened by Burjeel Holdings, a leading super-specialty healthcare services provider in the GCC.

Held on the sidelines of the 81st United Nations General Assembly (UNGA) in New York, the discussion focused on the economic and clinical impact of the global women’s health gap, which the World Economic Forum estimates could exceed $1 trillion annually by 2040 if left unaddressed.

The roundtable, opened with a virtual address from HRH Ambassador Reema Bandar Al-Saud, Ambassador of the Kingdom of Saudi Arabia to the United States, speaking about the need to take a more comprehensive approach to women’s health.

“It begins with knowledge and prevention,” said Princess Reema in her video address. “It begins with creating an environment where women feel comfortable speaking about their health and asking for the care they need. But today, that conversation has to go much further. We have to invest in women everywhere. Women’s physical and mental health and overall well-being are interconnected, and our approach to care has to be, too. No nation can ask half of its people to contribute to its future and then leave their healthcare to chance.”

Dr. Shamsheer Vayalil, Chairman, and CEO of Burjeel Holdings, continued the discussion with 23 leaders spanning health systems, investment, philanthropy, and multilateral organizations. He pointed out how Burjeel Holdings’ clinical experience serves as an example of targeted investment in women’s healthcare as a scalable action, already improving the future of women, evidenced by the decline in cervical cancer cases at Burjeel Cancer Institute in the UAE over the past two years.

The Group also previewed collaborative initiatives under development in Saudi Arabia, including an integrated model for women’s health delivery that could be adapted for other markets, including across Africa and the wider Global South.

“Women’s health has been under-researched, underfunded, and too often treated as episodic rather than lifelong,” said Dr. Shamsheer Vayalil during his opening remarks. “Prevention is key, alongside diagnostics, cardiovascular health, cancer, reproductive health, menopause and midlife care, and so much more. Any model implemented needs to be evidence-based, culturally relevant, with trusted, measurable success. Only then will progress be seen.”

Ms. Khadija Rejto, Chair of Global Health at the Atria Research and Global health Institute emphasized this point, sharing, “Investors have long treated women’s health as a niche despite it being one of the fastest growing sectors in the world.”

As conversation continued, participants discussed three critical requirements for closing the women’s health gap: a sustained investment in women’s health systems, broader adoption of technology across care delivery, and new models of care with a demonstrated record of results.

About Burjeel Holdings

 Founded in 2007, Burjeel Holdings is a leading super-specialty healthcare services provider in the UAE and Oman, and it operates a growing specialized healthcare segment in Saudi Arabia. The Group operates an integrated and multi-brand healthcare ecosystem across primary, secondary, tertiary, and quaternary medical care, ensuring complex care delivery to patients across all socioeconomic groups. The network comprises 94 assets across the UAE, Oman, and Saudi Arabia, including 20 hospitals, 44 medical centers and physiotherapy centers, 16 pharmacies, and 14 other allied services. Burjeel Holdings’ brands include Burjeel, Medeor, LLH, Lifecare, Alkalma, and Tajmeel.

SOURCE Burjeel Holdings

Esta financiación acelerará la I+D, la expansión global al mercado y una importante presencia en Silicon Valley, mientras Brahma AI desarrolla el sistema operativo para contenido audiovisual empresarial

LOS ÁNGELES, LONDRES y BOMBAY, 25 de septiembre de 2026 — Brahma AI, el sistema operativo nativo de IA para contenido audiovisual empresarial, ha dado a conocer hoy que ha recaudado 150 millones de dólares mediante la emisión de acciones preferentes con una inversión de 100 millones de dólares por parte de Multiples Alternate Asset Management. La compañía también ha recibido otros 100 millones de dólares de interés por parte de los inversores.

Brahma AI se centra en cuatro sectores verticales globales: medios y entretenimiento, deportes, salud y publicidad. Entre sus principales clientes globales se encuentran Warner Bros., la NBA y la Clínica Mayo, y entre sus socios estratégicos de distribución figuran Google, Hakuhodo y DNEG.

Prabhu Narasimhan es el fundador y consejero delegado de Brahma AI, que nació de la visión de Narasimhan de integrar la tecnología y las capacidades desarrolladas en DNEG, Metaphysic y Prime Focus Technologies para crear una plataforma nativa de IA para las mayores empresas del mundo. Bajo su liderazgo, Brahma AI ha desarrollado su plataforma nativa de IA en torno a Brahma AI Core y Brahma AI Studio, ha conseguido importantes clientes y alianzas globales, y ha ampliado la aplicación de su tecnología en los sectores de medios y entretenimiento, deportes, salud y publicidad.

En la actualidad, Brahma AI combina la inteligencia y la gestión de contenido empresarial con sofisticadas tecnologías de creación de IA que abarcan IA visual, humanos digitales, voz y rendimiento multilingüe. Su tecnología ha recibido un importante reconocimiento en el sector, incluido un premio Emmy® de Tecnología e Ingeniería en 2026.

Jo Plaete, cofundador y director de tecnología, y uno de los principales expertos mundiales en IA, IA visual, humanos digitales y medios sintéticos de alta fidelidad, dirige la división de tecnología e I+D de Brahma AI mientras la empresa continúa desarrollando y expandiendo su plataforma de IA.

Renuka Ramnath, fundador, director y consejero delegado de Multiples, comentó:

“Brahma AI está reinventando la cadena de suministro de contenido en la era de la IA. Contando con una trayectoria única en tecnología de vanguardia e innovación empresarial, la compañía ayuda a las organizaciones a generar mayor valor a través de contenido, inteligencia, localización, humanos digitales y automatización de flujos de trabajo impulsados por IA. Su sólida captación de clientes, sus capacidades diferenciadas y el reconocimiento recibido, incluyendo un premio Emmy® de Tecnología e Ingeniería en 2026, suponen un refuerzo de cara a nuestra convicción en su capacidad para aprovechar la oportunidad de mercado multimillonaria”.

“Nuestra inversión está basada en la creencia de que toda empresa se está convirtiendo en una empresa de contenido. Prabhu, Jo y el resto del equipo aportan un profundo conocimiento de los sectores a los que sirven y han transformado la IA de vanguardia en soluciones altamente relevantes, desde la habilitación de experiencias visuales multilingües para películas hasta el desarrollo de gemelos digitales para médicos. Multiples Private Equity será un socio activo mientras la compañía navega por la siguiente fase de crecimiento a través de inversiones en I+D, expansión del mercado global y desarrollo de talento y procesos. La compañía tiene todos los ingredientes necesarios para construir una institución global duradera en un sector que apenas comienza a tomar forma”.

Namit Malhotra, fundador y consejero delegado de DNEG, afirmó:

“Brahma AI nació de la audaz idea de Prabhu: reunir las tecnologías y capacidades desarrolladas en DNEG, Metaphysic y Prime Focus Technologies para crear una nueva empresa tecnológica independiente, diseñada para la era de la IA. Lo que él y su equipo han construido a partir de esos cimientos en tan poco tiempo ha sido extraordinario”.

“A través del liderazgo de Prabhu, Brahma AI ha desarrollado su propia tecnología y productos, ha conseguido importantes clientes y alianzas globales, y ha establecido una identidad y ambición propias y claras. Este momento tiene una simetría especial. Prabhu, United Al Saqer Group y Thor Björgólfsson respaldaron e invirtieron en Prime Focus Limited, DNEG y en mí en una etapa crucial de nuestro desarrollo. En la actualidad, todos nosotros apoyamos a Brahma AI y a Prabhu junto con nuevos inversores liderados por Multiples”.

Prabhu Narasimhan, fundador y consejero delegado de Brahma AI, indicó:

“Lo que más me entusiasma de esta inversión es lo que nos permite construir a continuación. Nos encontramos cerca de lanzar humanos digitales interactivos, estamos desarrollando Brahma AI para que sea compatible con cualquier modelo y estamos llevando nuestra tecnología a casos de uso completamente nuevos. La seguridad, la autenticidad y la procedencia son pasos fundamentales dentro de todo lo que estamos creando”.

“Lo que nos atrajo de Multiples es nuestra convicción compartida de que las empresas que definen su categoría se construyen mediante una combinación de ambición audaz, ejecución disciplinada y visión a largo plazo. Me entusiasma enormemente contar con Multiples a nuestro lado mientras nos expandimos globalmente y seguimos ampliando los límites de la IA empresarial”.

Cantor Fitzgerald & Co. actuó como único agente colocador en esta financiación de capital.

Acerca de Brahma AI

Brahma AI es el sistema operativo nativo de IA para contenido audiovisual empresarial. Su plataforma combina Brahma AI Core, su capa de gestión e inteligencia de contenido empresarial, con Brahma AI Studio, su plataforma de creación impulsada por IA que abarca IA visual, humanos digitales, voz y rendimiento multilingüe. Brahma AI trabaja con algunos de los principales propietarios de contenido y empresas del mundo y recibió un premio Emmy® de Tecnología e Ingeniería en 2026 por su tecnología de IA visual.

Mente²: Emoción humana. Ejecución por máquina.

Acerca de Multiples

Multiples es la empresa líder en gestión de activos alternativos de la India, reconocida por su larga y exitosa trayectoria colaborando con emprendedores. Multiples ha proporcionado respaldo a más de 35 empresas con el objetivo de construir negocios ambiciosos, distintivos y responsables. Multiples identifica oportunidades que se benefician de grandes transformaciones en los sectores que elige y se asocia con emprendedores y equipos directivos excepcionales para generar un crecimiento transformador.

Multiples se centra en sectores clave como los servicios financieros, la industria farmacéutica y sanitaria, el consumo y la tecnología, y más recientemente, la economía verde. Algunas de las empresas con las que Multiples mantiene alianzas de inversión más destacadas son ACKO, Delhivery, Encube Ethicals, India Energy Exchange, Kogta Financial, Licious, Milltec, MoEngage, PVR, Quantiphi, TI Clean Mobility, Vastu Housing Finance, VIP Industries y Zenex.